it was not designed (in part) to provide resistance against the 282T mutant, that was a lucky coincidence which was not expected.
The paper you referenced was published in March 2011. Here's a VRUS PR from April 2010 which proves the company was aware that PSI-938 was active against 282T.
Pharmasset's purine analogs retain activity against the S282T mutation associated with in vitro resistance in other nucleoside/tide analogs in development, and are metabolized to the active triphosphate form through a different phosphorylation pathway than the pyrimidine analogs.
Other purine analogs under development are unable to make such a claim.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.